Biogen-话题@MedSci

#Biogen#

21篇内容 | 3669人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1404349, encodeId=61b0140434998, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, objectTitle=Eisai和Biogen正在向FDA申请aducanumab治疗阿尔茨海默症的优先审查, objectType=article, longId=199065, objectId=9d351990652f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d351990652f, replyNumber=0, likeNumber=88, createdTime=2020-08-11, rootId=0, userName=qjddjq, userId=0dab2457651, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d351990652f, moduleTitle=Eisai和Biogen正在向FDA申请aducanumab治疗阿尔茨海默症的优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d351990652f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404348, encodeId=fc0e14043483b, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, objectTitle=知名药企Biogen开会，4人感染新冠肺炎, objectType=article, longId=189593, objectId=bf43189593b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf43189593b9, replyNumber=0, likeNumber=61, createdTime=2020-03-10, rootId=0, userName=qjddjq, userId=0dab2457651, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf43189593b9, moduleTitle=知名药企Biogen开会，4人感染新冠肺炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf43189593b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404347, encodeId=0a17140434e31, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, objectTitle=Biogen以27亿美元与基因编辑公司Sangamo签署协议，再次在阿尔茨海默氏病领域巨额投资, objectType=article, longId=189183, objectId=0b3318918384, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b3318918384, replyNumber=0, likeNumber=71, createdTime=2020-03-04, rootId=0, userName=qjddjq, userId=0dab2457651, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b3318918384, moduleTitle=Biogen以27亿美元与基因编辑公司Sangamo签署协议，再次在阿尔茨海默氏病领域巨额投资, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b3318918384)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404346, encodeId=8d8b140434693, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, objectTitle=Biogen将从辉瑞购买实验性阿尔茨海默症/帕金森病药物PF-05251749, objectType=article, longId=186231, objectId=eaa1186231a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eaa1186231a9, replyNumber=0, likeNumber=74, createdTime=2020-01-15, rootId=0, userName=qjddjq, userId=0dab2457651, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eaa1186231a9, moduleTitle=Biogen将从辉瑞购买实验性阿尔茨海默症/帕金森病药物PF-05251749, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eaa1186231a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404345, encodeId=0b9314043458b, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, objectTitle=Biogen以4500万美元收购Ionis早期阿尔茨海默氏症药物--靶向tau蛋白, objectType=article, longId=185043, objectId=660818504339, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=660818504339, replyNumber=0, likeNumber=69, createdTime=2019-12-23, rootId=0, userName=qjddjq, userId=0dab2457651, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=660818504339, moduleTitle=Biogen以4500万美元收购Ionis早期阿尔茨海默氏症药物--靶向tau蛋白, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=660818504339)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404344, encodeId=5bb6140434422, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, objectTitle=Biogen宣布BDCA2单抗BIIB059在皮肤性红斑狼疮和系统性红斑狼疮的2期研究阳性结果, objectType=article, longId=184168, objectId=6fdd184168d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fdd184168d5, replyNumber=0, likeNumber=69, createdTime=2019-12-06, rootId=0, userName=qjddjq, userId=0dab2457651, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fdd184168d5, moduleTitle=Biogen宣布BDCA2单抗BIIB059在皮肤性红斑狼疮和系统性红斑狼疮的2期研究阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fdd184168d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404343, encodeId=5e3c14043433d, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, objectTitle=美国临床医生最喜欢哪款多发性硬化症药物？诺华、默克还是Biogen的？, objectType=article, longId=183458, objectId=aa7d1834581c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa7d1834581c, replyNumber=0, likeNumber=46, createdTime=2019-11-24, rootId=0, userName=qjddjq, userId=0dab2457651, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa7d1834581c, moduleTitle=美国临床医生最喜欢哪款多发性硬化症药物？诺华、默克还是Biogen的？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa7d1834581c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404342, encodeId=a6b41404342ab, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, objectTitle=分析师表示，FDA对Biogen的阿尔茨海默症药物的裁决可能是"政治决定", objectType=article, longId=182456, objectId=10d018245665, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=10d018245665, replyNumber=0, likeNumber=69, createdTime=2019-11-07, rootId=0, userName=qjddjq, userId=0dab2457651, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=10d018245665, moduleTitle=分析师表示，FDA对Biogen的阿尔茨海默症药物的裁决可能是"政治决定", moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=10d018245665)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404341, encodeId=7fa6140434117, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, objectTitle=Biogen的aducanumab治疗阿尔茨海默氏病符合III期试验终点, objectType=article, longId=181870, objectId=66f71818e0a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66f71818e0a7, replyNumber=0, likeNumber=92, createdTime=2019-10-26, rootId=0, userName=qjddjq, userId=0dab2457651, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66f71818e0a7, moduleTitle=Biogen的aducanumab治疗阿尔茨海默氏病符合III期试验终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66f71818e0a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404340, encodeId=355414043406d, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, objectTitle=大逆转，曾终止临床三期的AD药物aducanumab将申请上市昨日（10月22日），渤健（Biogen）和卫材（Eisai）联合宣布，在与美国FDA沟通后，渤健, objectType=article, longId=181821, objectId=ade018182134, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ade018182134, replyNumber=0, likeNumber=66, createdTime=2019-10-25, rootId=0, userName=qjddjq, userId=0dab2457651, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ade018182134, moduleTitle=大逆转，曾终止临床三期的AD药物aducanumab将申请上市昨日（10月22日），渤健（Biogen）和卫材（Eisai）联合宣布，在与美国FDA沟通后，渤健, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ade018182134)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404339, encodeId=c3ef1404339be, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, objectTitle=Biogen将向FDA申请阿尔茨海默症治疗药物Aducanumab的监管备案, objectType=article, longId=181799, objectId=6cee181e9981, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cee181e9981, replyNumber=0, likeNumber=61, createdTime=2019-10-24, rootId=0, userName=qjddjq, userId=0dab2457651, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cee181e9981, moduleTitle=Biogen将向FDA申请阿尔茨海默症治疗药物Aducanumab的监管备案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cee181e9981)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404338, encodeId=49401404338b7, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, objectTitle=由于安全性问题，Biogen停止其TGF-β单抗BG00011治疗特发性肺纤维化的中期研究, objectType=article, longId=179684, objectId=ff601e968408, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff601e968408, replyNumber=0, likeNumber=56, createdTime=2019-09-20, rootId=0, userName=qjddjq, userId=0dab2457651, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff601e968408, moduleTitle=由于安全性问题，Biogen停止其TGF-β单抗BG00011治疗特发性肺纤维化的中期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff601e968408)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404337, encodeId=be10140433ec5, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, objectTitle=阿尔茨海默症治疗再遇挫折：Eisai和Biogen终止了BACE抑制剂elenbecestat的研发, objectType=article, longId=179448, objectId=9f5b1e9448be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f5b1e9448be, replyNumber=0, likeNumber=64, createdTime=2019-09-16, rootId=0, userName=qjddjq, userId=0dab2457651, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f5b1e9448be, moduleTitle=阿尔茨海默症治疗再遇挫折：Eisai和Biogen终止了BACE抑制剂elenbecestat的研发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f5b1e9448be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404336, encodeId=893c14043361e, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, objectTitle=Biogen公司8亿美元收购Nightstar，以获取其眼科疾病的基因疗法管线, objectType=article, longId=167847, objectId=b9f016e8475d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9f016e8475d, replyNumber=0, likeNumber=76, createdTime=2019-06-09, rootId=0, userName=qjddjq, userId=0dab2457651, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9f016e8475d, moduleTitle=Biogen公司8亿美元收购Nightstar，以获取其眼科疾病的基因疗法管线, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9f016e8475d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404335, encodeId=2e2014043359b, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, objectTitle=Syncona的Nightstar Therapeutics将以8.77亿美元被Biogen收购, objectType=article, longId=161654, objectId=1df1161654bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1df1161654bc, replyNumber=0, likeNumber=68, createdTime=2019-03-06, rootId=0, userName=qjddjq, userId=0dab2457651, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1df1161654bc, moduleTitle=Syncona的Nightstar Therapeutics将以8.77亿美元被Biogen收购, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1df1161654bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404334, encodeId=8b82140433474, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, objectTitle=Alkermes和Biogen宣布美国FDA接受了Diroximel富马酸盐治疗多发性硬化症的新药申请 , objectType=article, longId=161249, objectId=55e816124925, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55e816124925, replyNumber=0, likeNumber=63, createdTime=2019-02-28, rootId=0, userName=qjddjq, userId=0dab2457651, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55e816124925, moduleTitle=Alkermes和Biogen宣布美国FDA接受了Diroximel富马酸盐治疗多发性硬化症的新药申请 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55e816124925)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404333, encodeId=dfe714043330a, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, objectTitle=英国NICE拒绝了Biogen的Spinraza治疗遗传性脊髓性肌萎缩症, objectType=article, longId=146658, objectId=8dd1146658a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8dd1146658a8, replyNumber=0, likeNumber=63, createdTime=2018-08-16, rootId=0, userName=qjddjq, userId=0dab2457651, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8dd1146658a8, moduleTitle=英国NICE拒绝了Biogen的Spinraza治疗遗传性脊髓性肌萎缩症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8dd1146658a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404332, encodeId=af591404332e2, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, objectTitle=Biogen、Samsung Bioepis和Abbvie的Humira 专利纠纷, objectType=article, longId=134447, objectId=fab413444e39, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fab413444e39, replyNumber=0, likeNumber=85, createdTime=2018-04-08, rootId=0, userName=qjddjq, userId=0dab2457651, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fab413444e39, moduleTitle=Biogen、Samsung Bioepis和Abbvie的Humira 专利纠纷, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fab413444e39)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404331, encodeId=428214043317e, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, objectTitle=Biogen与AbbVie正式宣布：多发性硬化症药物达利珠单抗退市, objectType=article, longId=131542, objectId=9be113154202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9be113154202, replyNumber=0, likeNumber=61, createdTime=2018-03-07, rootId=0, userName=qjddjq, userId=0dab2457651, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9be113154202, moduleTitle=Biogen与AbbVie正式宣布：多发性硬化症药物达利珠单抗退市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9be113154202)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404330, encodeId=f839140433061, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, objectTitle=期望已久的Biogen阿兹海默病临床结果新鲜出炉, objectType=article, longId=84194, objectId=517c8419471, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=517c8419471, replyNumber=0, likeNumber=61, createdTime=2016-12-15, rootId=0, userName=qjddjq, userId=0dab2457651, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=517c8419471, moduleTitle=期望已久的Biogen阿兹海默病临床结果新鲜出炉, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=517c8419471)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Biogen

2020-05-29

qjddjq (审核中...)

前往app查看评论内容

#Biogen#

Eisai和Biogen正在向FDA申请aducanumab治疗阿尔茨海默症的优先审查

2020-08-11

qjddjq (审核中...)

前往app查看评论内容

#Biogen#

知名药企Biogen开会，4人感染新冠肺炎

2020-03-10

qjddjq (审核中...)

前往app查看评论内容

#Biogen#

Biogen以27亿美元与基因编辑公司Sangamo签署协议，再次在阿尔茨海默氏病领域巨额投资

2020-03-04

qjddjq (审核中...)

前往app查看评论内容

#Biogen#

Biogen将从辉瑞购买实验性阿尔茨海默症/帕金森病药物PF-05251749

2020-01-15

qjddjq (审核中...)

前往app查看评论内容

#Biogen#

Biogen以4500万美元收购Ionis早期阿尔茨海默氏症药物--靶向tau蛋白

2019-12-23

qjddjq (审核中...)

前往app查看评论内容

#Biogen#

Biogen宣布BDCA2单抗BIIB059在皮肤性红斑狼疮和系统性红斑狼疮的2期研究阳性结果

2019-12-06

qjddjq (审核中...)

前往app查看评论内容

#Biogen#

美国临床医生最喜欢哪款多发性硬化症药物？诺华、默克还是Biogen的？

2019-11-24

qjddjq (审核中...)

前往app查看评论内容

#Biogen#

分析师表示，FDA对Biogen的阿尔茨海默症药物的裁决可能是"政治决定"

2019-11-07

qjddjq (审核中...)

前往app查看评论内容

#Biogen#

Biogen的aducanumab治疗阿尔茨海默氏病符合III期试验终点

2019-10-26

qjddjq (审核中...)

前往app查看评论内容

#Biogen#

大逆转，曾终止临床三期的AD药物aducanumab将申请上市昨日（10月22日），渤健（Biogen）和卫材（Eisai）联合宣布，在与美国FDA沟通后，渤健

2019-10-25

qjddjq (审核中...)

前往app查看评论内容

#Biogen#

Biogen将向FDA申请阿尔茨海默症治疗药物Aducanumab的监管备案

2019-10-24

qjddjq (审核中...)

前往app查看评论内容

#Biogen#

由于安全性问题，Biogen停止其TGF-β单抗BG00011治疗特发性肺纤维化的中期研究

2019-09-20

qjddjq (审核中...)

前往app查看评论内容

#Biogen#

阿尔茨海默症治疗再遇挫折：Eisai和Biogen终止了BACE抑制剂elenbecestat的研发

2019-09-16

qjddjq (审核中...)

前往app查看评论内容

#Biogen#

Biogen公司8亿美元收购Nightstar，以获取其眼科疾病的基因疗法管线

2019-06-09

qjddjq (审核中...)

前往app查看评论内容

#Biogen#

Syncona的Nightstar Therapeutics将以8.77亿美元被Biogen收购

2019-03-06

qjddjq (审核中...)

前往app查看评论内容

#Biogen#

Alkermes和Biogen宣布美国FDA接受了Diroximel富马酸盐治疗多发性硬化症的新药申请 

2019-02-28

qjddjq (审核中...)

前往app查看评论内容

#Biogen#

英国NICE拒绝了Biogen的Spinraza治疗遗传性脊髓性肌萎缩症

2018-08-16

qjddjq (审核中...)

前往app查看评论内容

#Biogen#

Biogen、Samsung Bioepis和Abbvie的Humira 专利纠纷

2018-04-08

qjddjq (审核中...)

前往app查看评论内容

#Biogen#

Biogen与AbbVie正式宣布：多发性硬化症药物达利珠单抗退市

2018-03-07

qjddjq (审核中...)

前往app查看评论内容

#Biogen#

期望已久的Biogen阿兹海默病临床结果新鲜出炉

2016-12-15

科室
- - 订阅+
  - 更多科室
工具
服务